Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen.
about
P1343
HLA class I and II genotype of the NCI-60 cell linesShort tandem repeat profiling provides an international reference standard for human cell linesA gene expression database for the molecular pharmacology of cancerA dual-fluorescence high-throughput cell line system for probing multidrug resistance.Enhancing the anticancer properties of cardiac glycosides by neoglycorandomizationAntitumor Activity of IMC-038525, a Novel Oral Tubulin Polymerization Inhibitor.Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer.Molecular mechanisms of drug resistance in single-step and multi-step drug-selected cancer cells.Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cellsAnalysis of TP53 mutation status in human cancer cell lines: a reassessmentGalectin-3 Binding Protein Secreted by Breast Cancer Cells Inhibits Monocyte-Derived Fibrocyte Differentiation.Establishment and Biological Characterization of a Panel of Glioblastoma Multiforme (GBM) and GBM Variant Oncosphere Cell LinesThailandepsins are new small molecule class I HDAC inhibitors with potent cytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapyBeyond the imaging: limitations of cellular uptake study in the evaluation of nanoparticles.Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer.A leukotriene B4 receptor-2 is associated with paclitaxel resistance in MCF-7/DOX breast cancer cellsFunctional characterization and anti-cancer action of the clinical phase II cardiac Na+/K+ ATPase inhibitor istaroxime: in vitro and in vivo properties and cross talk with the membrane androgen receptor.Sponge-derived fijianolide polyketide class: further evaluation of their structural and cytotoxicity properties.Is resistance useless? Multidrug resistance and collateral sensitivity.TR3 modulates platinum resistance in ovarian cancer.Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib.Overcoming ABCG2-mediated drug resistance with imidazo-[1,2-b]-pyridazine-based Pim1 kinase inhibitors.MCF-7/ADR cells (re-designated NCI/ADR-RES) are not derived from MCF-7 breast cancer cells: a loss for breast cancer multidrug-resistant research.A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance.Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1-R10.Essential role for gene profiling analysis in the authentication of human cell lines.Drug-resistant breast carcinoma (MCF-7) cells are paradoxically sensitive to apoptosis.Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure.Synergism of cytotoxic effects of vinorelbine and paclitaxel in vitro.Identification of CD44 as a surface biomarker for drug resistance by surface proteome signature technology.Dual secured nano-melittin for the safe and effective eradication of cancer cells.Taccalonolide Microtubule Stabilizers Generated Using Semisynthesis Define the Effects of Mono Acyloxy Moieties at C-7 or C-15 and Disubstitutions at C-7 and C-25.
P2860
Q24805062-9514F875-F1A9-4E30-8595-A9E1B4DC8768Q27910569-E1640FCB-108D-426F-BBB0-DA13B6285178Q29619242-A3BEC7FF-E7E1-4E59-843D-482627F90C3DQ33472881-AD2DDB5D-0036-4FF2-A422-97AAAE67DF38Q33933859-0A88D248-3A1B-42DF-A7E6-E4442D84F937Q34111215-F379F4B8-768A-4BA4-A5B6-DA33C6AEEDD7Q34661616-610DE6F8-9BD0-459F-A870-B78DE2AF32FBQ34996536-F9C6F0E7-9F40-43BE-AECA-4583412B0B78Q35141937-DC1AE0DE-F59A-4092-AF05-7CD4D39ABAFDQ35556954-3BE3F83C-3196-463C-93C7-0D466353F273Q35671197-460FE4BB-F8EC-4203-9284-254F02A30EC3Q35931701-1926DCEA-FF46-4733-8C97-F293C1E309EAQ35974087-6245C1F7-CF69-4447-B144-A7C31EFA9058Q36088241-12EE07FC-E104-4C84-9CF5-5BA6857757E2Q36247616-65B73AD5-555C-4FF8-A4A9-FEF8A3B242F9Q36521908-A66F7E08-56F2-432E-98D8-EC81F8BAD002Q37040640-8C1C494D-E577-43BB-9CD7-C3899CE60E40Q37269322-EAC04C97-5AAA-4EA1-BC3C-FE1A4AD8740DQ37409426-493EDD39-D9A5-4CDD-818F-8F98B9B1C46BQ37414081-14E97778-90DD-4549-BB66-64AAAE1F05C4Q37620325-14BE4D8B-0431-4DB7-A39C-100174DC2868Q38756596-2609806D-CAA6-412B-9CC5-07078FE6CAD8Q38836775-033A6098-D30F-4D4B-B881-C1FB32EC5559Q39625971-202E8E6A-E245-4DE2-A619-33D4030CDAB8Q40136335-23118230-1A2A-4B3C-82DC-781C1DCCB456Q40238116-886B0B22-D050-4109-9924-B7876A6739DEQ40286863-38C96F67-6482-4195-903F-52EB6830BFF3Q40549790-23EF2E3E-B6A0-4015-87F7-D27E99952EFDQ40574551-C797485E-9B7F-4CDB-A4AF-1BCE673156E8Q40838746-5CC9BCBE-3CE0-452C-8202-AE9D8389D8BBQ41983563-D9E64967-DB4A-4E11-9516-19490689CE85Q42583845-4C1EFF9D-DFC5-42C3-9F58-720280ACDD4BQ48185206-B2E53263-1851-4EBD-830D-6F647A07CDF0
P2860
Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen.
@en
Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen.
@nl
type
label
Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen.
@en
Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen.
@nl
prefLabel
Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen.
@en
Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen.
@nl
P2093
P356
P1476
Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen.
@en
P2093
Sausville EA
Scudiero DA
P356
10.1093/JNCI/90.11.862
P407
P4510
P577
1998-06-01T00:00:00Z